Objective  To evaluate the efficacy, safety and economy of crisaborole in the treatment of mild-to-moderate atopic dermatitis (AD), and to provide evidence-based reference for the clinical drug use.

Methods  Rapid health technology assessment (rHTA) was used to systematically search the PubMed, Embase, Cochrane Library, Web of Science, CNKI, WanFang Data, VIP, SinoMed databases, and official websites of domestic foreign health technology assessment (HTA) organizations. The HTA reports, systematic reviews/Meta-analysis and pharmacoeconomic studies about crisaborole in the treatment of mild-to-moderate AD were collected according to the inclusion and exclusion criteria. The retrieval time was from the inception to August 15th, 2025. After data extraction and quality evaluation, descriptive analyses were performed on the results of the included studies.

Results  A total of 19 pieces of literature were included, involving 16 systematic reviews/Meta-analysis, 2 HTA reports and 1 pharmacoeconomic studies. In terms of efficacy, compared with placebo or vehicle, crisaborole significantly improved Eczema Area and Severity Index (EASI), Investigator’s Static Global Assessment (ISGA), Scoring of Atopic Dermatitis (SCORAD), and Pruritus Numerical Rating Scale (NRS) scores in patients, improving skin condition, and alleviating symptoms such as itching. However, no definitive conclusions had been reached regarding its efficacy compared with topical calcineurin inhibitors. In terms of safety, the primary adverse events (AE) of crisaborole were application site reactions, which occured at a relatively low rate overall. Most cases were mild to moderate in severity, with fewer serious adverse events (SAE) reported. Treatment discontinuation was generally not required, and the medication was well-tolerated in patients. In terms of economy, Canadian studies indicated that crisaborole had an economic advantage compared with pimecrolimus in the treatment of children with mild-to-moderate AD, while economic evaluation data from China remained unavailable.

Conclusion  Crisaborole has good efficacy and safety in the treatment of mild-to-moderate AD, but its economy need to be studied.

1.中华医学会, 中华医学会杂志社, 中华医学会皮肤性病学分会, 等. 儿童特应性皮炎基层诊疗指南（2023年）[J]. 中华全科医师杂志, 2023, 22(1): 8-18. [Chinese Medical Association, Chinese Medical Association Publishing House, Chinese Society of Dermatology, et al. Guideline for primary care of atopic dermatitis in children(2023)[J]. Chinese Journal of General Practitioners, 2023, 22(1): 8-18.] DOI: 10.3760/cma.j.cn114798-20220915-00924.

2.吴盼倩, 舒虹. 特应性皮炎流行病学及疾病负担研究进展 [J]. 中国实用儿科杂志, 2023, 38(9): 700-704. [Wu PQ, Shu H. Research progress in epidemiology and burden of disease in atopic dermatitis[J]. Chinese Journal of Practical Pediatrics, 2023, 38(9): 700-704.] DOI: 10.19538/j.ek2023090610.

3.彭寒梅, 蒋运兰, 李洁, 等. 中国0~18岁人群特应性皮炎患病率及影响因素的Meta分析[J]. 包头医学院学报, 2023, 39(3): 55-61, 79. [Peng HM, Jiang YL, Li J, et al. Prevalence and influencing factors of atopic dermatitis in people aged 0~18 years in China: a Meta-analysis[J]. Journal of Baotou Medical College, 2023, 39(3): 55-61, 79.] DOI: 10.16833/j.cnki.jbmc.2023.03.012.

4.王建琴. 中国特应性皮炎诊疗指南（2020版）解读[J]. 皮肤性病诊疗学杂志, 2020, 27(5): 359-361. [Wang JQ. Interpretation of Chinese guidelines for the diagnosis and treatment of atopic dermatitis (2020)[J]. Journal of Diagnosis and Therapy on Dermato-venereology, 2020, 27(5): 359-361.] DOI: 10.3969/j.issn.1674-8468.2020.05.016.

5.Chovatiya R, Silverberg JI. Evaluating the longitudinal course of atopic dermatitis: implications for clinical practice[J]. Am J Clin Dermatol, 2022, 23(4): 459-468. DOI: 10.1007/s40257-022-00697-w.

6.聂智峰, 肖若薇, 宋佳芳, 等. 中国儿童特应性皮炎的疾病经济负担与医疗资源利用情况[J]. 中国药学（英文版）, 2024, 33(5): 458-469. [Nie ZF, Xiao RW, Song JF, et al. Economic burden and healthcare resource utilization of childhood atopic dermatitis in China[J]. Journal of Chinese Pharmaceutical Sciences, 2024, 33(5): 458-469.] DOI: 10.5246/jcps.2024.05.035.

7.Meena S, Gupta LK, Khare AK, et al. Topical corticosteroids abuse: a clinical study of cutaneous adverse effects[J]. Indian J Dermatol, 2017, 62(6): 675. DOI: 10.4103/ijd.IJD_110_17.

8.U.S. Food & Drug Administration. FDA Approves Updated Labeling with Boxed Warning and Medication Guide for Two Eczema Drugs, Elidel and Protopic[EB/OL]. (2006-01-19) [2025-11-24]. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fda-approves-updated-labeling-boxed-warning-and-medication-guide-two-eczema-drugs-elidel-and.

9.McDowell L, Olin B. Crisaborole: a novel nonsteroidal topical treatment for atopic dermatitis[J]. J Pharm Technol, 2019, 35(4): 172-178. DOI: 10.1177/8755122519844507.

10.鞠妍. 克立硼罗治疗炎症性皮肤病的研究进展[J]. 中国现代医生, 2024, 62(10): 114-117. [Ju Y. Research progress of crisaborole in the treatment of inflammatory skin diseases[J]. China Modern Doctor, 2024, 62(10): 114-117.] DOI: 10.3969/j.issn.1673-9701.2024.10.030.

11.覃方, 吴坤荣, 刘成裕, 等. 艾托格列净治疗2型糖尿病的快速卫生技术评估[J]. 药物流行病学杂志, 2024, 33(7): 778-789. [Qin F, Wu KR, Liu CY, et al. Ertugliflozin in the treatment of type 2 diabetes mellitus: a rapid health technology assessment[J]. Chinese Journal of Pharmacoepidemiology, 2024, 33(7): 778-789.] DOI: 10.12173/j.issn.1005-0698.202405068.

12.嵇承栋, 朱琳懿, 万悦竹, 等. 国际卫生技术评估机构协作网卫生技术评估报告清单解读[J]. 中国循证医学杂志, 2016, 16(3): 369-372. [Ji CD, Zhu LY, Wan YZ, et al. An introduction of reporting checklist of Health Technology Assessment developed by the International Network of Agencies for Health Technology Assessment[J]. Chinese Journal of Evidence-Based Medicine, 2016, 16(3): 369-372.] DOI: 10.7507/1672-2531.20160057.

13.张方圆, 沈傲梅, 曾宪涛, 等. 系统评价方法学质量评价工具AMSTAR 2解读[J]. 中国循证心血管医学杂志, 2018, 10(1): 14-18. [Zhang FY, Shen AM, Zeng XT, et al. An introduction to AMSTAR 2: a critical appraisal tool for systematic reviews[J]. Chinese Journal of Evidence-based Cardiovascular Medicine, 2018, 10(1): 14-18.] DOI: 10.3969/j.issn.1674-4055.2018.01.03.

14.陶立元, 甘戈, 刘珏. 卫生经济学评价报告标准2022解读 [J]. 中华流行病学杂志, 2023, 44(4): 667-672. [Tao LY, Gan G, Liu J. Interpretation of consolidated health economic evaluation reporting standards 2022[J]. Chinese Journal of Epidemiology, 2023, 44(4): 667-672.] DOI: 10.3760/cma.j.cn112338-20221127 -01002.

15.柯义君, 王威, 黄灿, 等. 维立西呱治疗心力衰竭有效性、安全性及经济性的快速卫生技术评估[J]. 中国药房, 2024, 35(15): 1818-1824. [Ke YJ, Wang W, Huang C, et al. Rapid health technology assessment of the efficacy, safety and cost-effectiveness of vericiguat in the treatment of heart failure[J]. China Pharmacy, 2024, 35(15): 1818-1824.] DOI: 10.6039/j.issn. 1001-0408.2024.15.04.

16.崔宏, 蔡秋晗, 李梅芳, 等. 克立硼罗软膏治疗特应性皮炎的系统评价[J]. 药物评价研究, 2024, 47(5): 1100-1110. [Cui H, Cai QH, Li MF, et al. Systematic review of crisaborole ointment in treatment of atopic dermatitis[J]. Drug Evaluation Research, 2024, 47(5): 1100-1110.] DOI: 10.7501/j.issn.1674-6376.2024.05.021.

17.沈伟杰, 林克胜, 吴黎明. 克立硼罗软膏与外用钙调神经磷酸酶抑制剂治疗轻中度特应性皮炎疗效和安全性比较网状Meta分析[J]. 浙江中西医结合杂志, 2025, 35(2): 165-170. [Shen WJ, Lin KS, Wu LM. Network Meta-analysis of efficacy and safety comparison between crisaborole ointment and topical calcineurin inhibitors in the treatment of mild-to-moderate atopic dermatitis[J]. Zhejiang Journal of integrated Traditional Chinese and Western Medicine, 2025, 35(2): 165-170.] DOI: 10.3969/j.issn.1005-4561.2025.02.016.

18.刘菁, 陈宏泉, 陆晓鸥, 等. 2%克立硼罗软膏治疗轻中度特应性皮炎安全性和有效性的Meta分析[J]. 临床医学进展, 2023, 13(4): 6835-6843. [Liu J, Chen HQ, Lu XO, et al. Efficacy and safety of 2% crisaborole ointment for mild to moderate atopic dermatitis: a Meta-analysis[J]. Advances in Clinical Medicine, 2023, 13(4): 6835-6843.] DOI: 10.12677/acm.2023.134956.

19.Fahrbach K, Tarpey J, Washington EB, et al. Crisaborole ointment, 2%, for treatment of patients with mild-to-moderate atopic dermatitis: systematic literature review and network Meta-analysis[J]. Dermatol Ther (Heidelb), 2020, 10(4): 681-694. DOI: 10.1007/s13555-020-00389-5.

20.Martín-Santiago A, Puig S, Arumi D, et al. Safety profile and tolerability of topical phosphodiesterase 4 inhibitors for the treatment of atopic dermatitis: a systematic review and Meta-analysis[J]. Curr Ther Res Clin Exp, 2022, 96: 100679. DOI: 10.1016/j.curtheres.2022.100679.

21.Yang H, Wang J, Zhang X, et al. Application of topical phosphodiesterase 4 inhibitors in mild to moderate atopic dermatitis: a systematic review and Meta-analysis[J]. JAMA Dermatol, 2019, 155(5): 585-593. DOI: 10.1001/jamadermatol. 2019.0008.

22.Ramachandran V, Cline A, Feldman SR, et al. Evaluating crisaborole as a treatment option for atopic dermatitis[J]. Expert Opin Pharmacother, 2019, 20(9): 1057-1063. DOI: 10.1080/14656566.2019.1604688.

23.He Y, Liu J, Wang Y, et al. Topical administration of crisaborole in mild to moderate atopic dermatitis: a systematic review and Meta-analysis[J]. Dermatologic Therapy, 2023, 2023(10): 1-9.  https://doi.org/10.1155/2023/1869934.

24.赵欣怡. 非甾体类外用药治疗特应性皮炎的有效性与安全性的网状Meta分析[D]. 沈阳: 中国医科大学, 2023. DOI: 10.27652/d.cnki.gzyku.2023.001593.

25.Alkattan A, Alzaher A, Alhabib D, et al. An evaluation of the recently approved drugs for treating atopic dermatitis in the context of their safety and efficacy: a systematic review and Meta-analysis[J]. Expert Rev Clin Immunol, 2025, 21(3): 347-357. DOI: 10.1080/1744666X.2024.2435657.

26.Murai H, Kawamoto N, Arima T, et al. New topical molecular targeted therapies for atopic dermatitis in children: a systematic review and Meta-analysis[J]. Pediatr Allergy Immunol, 2025, 36(6): e70122. DOI: 10.1111/pai.70122.

27.Cao XC, Lu JW, Feng YF, et al. Efficacy and safety of ruxolitinib, crisaborole, and tapinarof for mild-to-moderate atopic dermatitis: a Bayesian network analysis of RCTs[J]. Naunyn Schmiedebergs Arch Pharmacol, 2024, 397(7): 4657-4662. DOI: 10.1007/s00210-024-02971-6.

28.You J, Li H, Wang Z, et al . Evaluating efficacy and safety of crisaborole in managing childhood mild to moderate atopic dermatitis: a systematic review and Meta-analysis[J]. Br J Hosp Med (Lond), 2025, 86(1): 1-19. DOI: 10.12968/hmed.2024.0575.

29.Chu DK, Chu AWL, Rayner DG, et al. Topical treatments for atopic dermatitis (eczema): systematic review and network Meta-analysis of randomized trials[J]. J Allergy Clin Immunol, 2023, 152(6): 1493-1519. DOI: 10.1016/j.jaci.2023.08.030.

30.Lax SJ, Van Vogt E, Candy B, et al. Topical anti-inflammatory treatments for eczema: network Meta-analysis[J]. Cochrane Database Syst Rev, 2024, 8(8): CD015064. DOI: 10.1002/14651858.CD015064.pub2.

31.Zhang L, Du D, Wang L, et al. Efficacy and safety of topical Janus kinase and phosphodiesterase inhibitor-4 inhibitors for the treatment of atopic dermatitis: a network Meta-analysis[J]. J Dermatol, 2021, 48(12): 1877-1883. DOI: 10.1111/1346-8138.16126.

32.Canadian Agency for Drugs and Technologies in Health.Pharmacoeconomic review report: crisaborole ointment, 2% (Eucrisa)[R/OL]. (2019-04-17) [2025-09-16]. https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/sr0570-eucrisa-pharmacoeconomic-report.pdf.

33.Canadian Agency for Drugs and Technologies in Health. Clinical review report: crisaborole ointment, 2% (Eucrisa)[R/OL]. (2019-04-17) [2025-09-16]. https://www.cda-amc.ca/sites/default/files/cdr/clinical/sr0570-eucrisa-clinical-report.pdf.

34.National Institute for Health and Care Excellence. Crisaborole for treating mild to moderate atopic dermatitis in people 2 years and older (terminated appraisal)[R/OL]. (2020-09-11) [2025-09-16].https://www.nice.org.uk/guidance/ta701/documents/committee-papers.

35.Clinicaltrials.gov. A study of crisaborole ointment 2%; crisaborole vehicle; TCS and TCI in subjects aged ≥ 2 years, with mild-moderate AD[DB/OL]. (2022-01-10) [2025-11-24] https://clinicaltrials.gov/show/NCT03539601.

36.Paller AS, Tom WL, Lebwohl MG, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults[J]. J Am Acad Dermatol. 2016, 75(3): 494-503. e6. DOI: 10.1016/j.jaad.2016.05.046.

37.Eichenfield LF, Call RS, Forsha DW, et al. Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis[J]. J Am Acad Dermatol. 2017, 77(4): 641-649. e5. DOI: 10.1016/j.jaad.2017.06.010.

38.Chakraborty D, De A, Khan A, et al. Comparative evaluation of the efficacy and safety of crisaborole ointment (2%) versus tacrolimus ointment (0.1%) for the topical treatment of atopic dermatitis: an open-labeled single-blinded randomized controlled trial[J]. Int J Dermatol, 2025, 64(2): 402-404. DOI: 10.1111/ijd.17572.

39.肖星, 王珊, 杨欢, 等. 多中心随机对照临床试验观察2%克立硼罗软膏与1%吡美莫司乳膏治疗儿童轻中度特应性皮炎的疗效和安全性[J]. 中华皮肤科杂志, 2025, 58(5): 425-430. [Xiao X, Wang S, Yang H, et al. Comparison of efficacy and safety of crisaborole ointment 2% versus pimecrolimus cream 1% in the treatment of mild to moderate atopic dermatitis in children: a multicenter, randomized, controlled clinical trial[J]. Chinese Journal of Dermatology, 2025, 58(5): 425-430.] DOI: 10.35541/cjd.20240453.

40.马雪晴, 刘奔, 薛爱. 克立硼罗软膏与丁酸氢化可的松乳膏治疗轻中度特应性皮炎的临床效果及安全性比较[J]. 临床合理用药, 2024, 17(13): 97-100. [Ma XQ, Liu B, Xue A. Comparison of clinical efficacy and safety between crisaborole ointment and hydrocortisone butyrate cream in the treatment of mild to moderate atopic dermatitis[J]. Chinese Journal of Clinical Rational Drug Use, 2024, 17(13): 97-100.] DOI: 10.15887/j.cnki. 13-1389/r.2024.13.028.